COPD

Genomics, in combination with patient demographic risks, could help better inform clinicians of persons at risk for worsened chronic pulmonary burden.

Where do investigators go next with the 8000-plus COPD patient research?

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

New findings from ATS show the residual effects of vaping-associated lung distress.

A discussion with a study author on promising new findings for the combination inhaler therapy.

Little is understood about the systemic markers of worsening COPD. Investigators have observed at least 3 novel pathways.

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.

An assessment of FF/UMEC/VI in a single inhaler show its benefit in respiratory function among COPD patients at 24 weeks.

A new study shows consistent confidence and anxiety of self-care with the injectable biologic in patients with asthma.

An assessment of a combined pharmacologic and cognitive behavioral therapy program shows patients improve FEV1, FVC, and other metrics.

Despite being advised in clinical guidelines, fewer than 2% of COPD patients initiate pulmonary rehabilitation within 90 days of hospitalization.

California is home of the cities with the most unhealthy pollution levels, according to the newest annual report from the ALA.

ALA chief medical officer Al Rizzo, MD, discusses plans to kickstart vaccine research and public health preventive measures.

COPD patients with unnoticed OSA are at a greater risk of hospital readmission and even all-cause mortality.

Al Rizzo, MD, of the American Lung Association, discusses some of the biggest challenges and questions raised on lung health during the coronavirus pandemic.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.

A study of 416 hospitalized patients indicates 19.7% suffered cardiac injury, which was also associated with increased ventilation and mortality.

New expanded analysis from the IMPACT trial shows FF/UMEC/VI's benefit versus dual inhaler therapies.

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

The new low nicotine products contain 95% less nicotine than the top 100 cigarette brands in the US, according to 22nd Century Group.